Objectives Mesenchymal stromal cells (MSC) are characterised by their capacity to suppress immune reactions. This function was reported to be shared in vitro by fibroblasts but their role has been poorly investigated in vivo. This study explored whether fibroblasts isolated from skin may suppress the host immune response in a model of autoimmune disorder.
Methods and Results It was first confirmed that skin fibroblasts lack the capacity to differentiate into osteoblasts or chondrocytes but possess the capacity to inhibit in vitro the proliferation of T lymphocytes. Fibroblasts also secrete modulatory molecules, in particular prostaglandin E2 and nitric oxide, similar to MSC. To assess their role in vivo, the collagen-induced arthritis model was used, and showed that similar to MSC the intravenous injection of fibroblasts efficiently suppress clinical signs of arthritis and delay disease onset. This effect was associated with reduced inflammation as reflected by biological parameters and increased levels of IL-5, IL-10 and IL-13 in the spleens of treated mice. To characterise the mechanism of immunosuppression further, phenotypic analyses were performed and could not detect any induction of CD4 CD25 Foxp3+ regulatory T (Treg) cells. A population of CD4 IL-10+ T cells was, however, detected that was slightly increased after fibroblast injection and significantly upregulated after MSC administration.
Conclusions This study gives the first evidence for an immunosuppressive role of fibroblasts in vivo, and strongly suggests that fibroblasts induce a T-helper type 2 immune profile, although the possibility that IL-10-secreting Treg cells may be generated cannot be excluded.
Statistics from Altmetric.com
Funding Work in the laboratory Inserm U844 was supported by the Inserm Institute, the University of Montpellier I and a grant from the ‘Agence Nationale de la Recherche’ (project ANR Physio 2006 ‘Immunostem’).
Competing interests None.
Provenance and peer review Not commissioned; externally peer reviewed.